BeiGene (BeiGene) Change In Receivables : $-188 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is BeiGene Change In Receivables?

BeiGene's change in receivables for the quarter that ended in Dec. 2023 was $-45 Mil. It means BeiGene's Accounts Receivable increased by $45 Mil from Sep. 2023 to Dec. 2023 .

BeiGene's change in receivables for the fiscal year that ended in Dec. 2023 was $-188 Mil. It means BeiGene's Accounts Receivable increased by $188 Mil from Dec. 2022 to Dec. 2023 .

BeiGene's Accounts Receivable for the quarter that ended in Dec. 2023 was $358 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BeiGene's Days Sales Outstanding for the three months ended in Dec. 2023 was 51.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BeiGene's liquidation value for the three months ended in Dec. 2023 was $1,383 Mil.

BeiGene Change In Receivables Historical Data

The historical data trend for BeiGene's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Change In Receivables Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-29.82

10.36

-423.02

304.11

-188.31

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															19.40	-136.49	4.56	-11.59	-44.80

BeiGene Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-188 Mil.

BeiGene (NAS:BGNE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BeiGene's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	358.027	/	634.409	*	91
=	51.50

2. In Ben Graham's calculation of liquidation value, BeiGene's accounts receivable are only considered to be worth 75% of book value:

BeiGene's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3174.4	-	2267.948	+	0.75 * 358.027	+	0.5 * 416.122
=	1,383

BeiGene Change In Receivables Related Terms

Thank you for viewing the detailed overview of BeiGene's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (BeiGene) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (NAS:BGNE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

06160:Hong Kong 49B:Germany 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

Executives

Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Chan Henry Lee	officer: SVP, General Counsel	55 CAMBRIDGE PARKWAY, SUITE 700W, CAMBRIDGE MA 02142
Julia Aijun Wang	officer: Chief Financial Officer	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Lai Wang	officer: Global Head of R&D	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Xiaobin Wu	officer: President and GM China	C/O MOURANT OZANNES CRP SVCS CAYMAN LTD, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Hillhouse Capital Advisors, Ltd.	10 percent owner	OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Xiaodong Wang	director	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
John Oyler	director, 10 percent owner, officer: Chief Executive Office	C/O GENTA INC, 3550 GENERAL ATOMICS CT BLDG 9, SAN DIEGO CA 92121
Alessandro Riva	director	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Margaret Dugan	director	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Jane Huang	officer: CMO, Hematology	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Amgen Inc	10 percent owner	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Howard Liang	officer: CFO & CSO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Timothy Yung-cheng Chen	director	LSI LOGIC CORP, 1621 BARBER LANE, MILPITAS CA 95035